Bioanalysis

Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Friday, April 30, 2021 - 5:00am

b'ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia\'s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.\nLiz Doolin, Bionomics\' Vice President Clinical Development commented that "We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning.

Key Points: 
  • b'ADELAIDE, AUS, Apr 30, 2021 - (ACN Newswire) - Agilex Biolabs, Australia\'s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.\nLiz Doolin, Bionomics\' Vice President Clinical Development commented that "We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning.
  • "\nBionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), is a global, clinical stage biopharmaceutical company.
  • Agilex Biolabs has been working closely with Bionomics for several years, supporting the PK regulated Bioanalysis of BNC210 and is privileged to be a part of this potential new treatment for anxiety and stressor-related disorders.
  • Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials

Wednesday, April 28, 2021 - 8:00pm

Sales, Agilex Biolabs\' Director of Immunoassay, Ronald R. Bowsher PhD, Partner and Chief Scientific Officer at B2S Life Sciences, and Amy Rosen, Associate Director of Statistics at B2S.\nThe panel shared insights from many years working in immunoassay bioanalysis for clinical trials.

Key Points: 
  • Sales, Agilex Biolabs\' Director of Immunoassay, Ronald R. Bowsher PhD, Partner and Chief Scientific Officer at B2S Life Sciences, and Amy Rosen, Associate Director of Statistics at B2S.\nThe panel shared insights from many years working in immunoassay bioanalysis for clinical trials.
  • Ronald R. Bowsher said B2S has been working with Agilex Biolabs for more than four years, "Our relationship has evolved very well, and we understand each other\'s needs.
  • And despite the geographic differences, I think we\'ve had a very productive collaboration serving Agilex Biolabs\' customers," he said.\nDr Kurt J.
  • We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.\n'

Comparison of Hybrid LCMS & Ligand Binding Assays for Bioanalysis, Upcoming Webinar Hosted by Xtalks

Monday, April 5, 2021 - 1:30pm

TORONTO, April 5, 2021 /PRNewswire-PRWeb/ -- Historically, bioanalytical support for large molecule development has utilized ligand binding (LBA) technologies.

Key Points: 
  • TORONTO, April 5, 2021 /PRNewswire-PRWeb/ -- Historically, bioanalytical support for large molecule development has utilized ligand binding (LBA) technologies.
  • Hybrid mass spectrometry only requires one reagent for enrichment and this reagent does not need to be extremely selective.
  • In the past, our ligand binding team provided the majority of our large molecule bioanalysis support.
  • For more information, or to register for this event, visit Comparison of Hybrid LCMS & Ligand Binding Assays for Bioanalysis.

Agilex Biolabs Showcases Advanced Immunoassay and Immunobiology Services at Bio-Europe Spring 2021

Wednesday, March 17, 2021 - 7:00am

ADELAIDE, AU, Mar 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.

Key Points: 
  • ADELAIDE, AU, Mar 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
  • Sales Agilex Biolabs' Director Immunoassay said:
    "Our experienced team can develop or transfer a method for any biologic to support pre-clinical GLP or clinical studies.
  • Agilex Biolabs also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.
  • We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Immunologix Laboratories Expands Translational Sciences Team

Tuesday, February 16, 2021 - 3:07pm

TAMPA, Fla., Feb. 16, 2021 /PRNewswire/ -- Immunologix Laboratories announces two additions to the Translational Sciences division with Corinna Fiorotti, Ph.D .

Key Points: 
  • TAMPA, Fla., Feb. 16, 2021 /PRNewswire/ -- Immunologix Laboratories announces two additions to the Translational Sciences division with Corinna Fiorotti, Ph.D .
  • The continued growth of Translational Sciences highlights Immunologix Laboratories' commitment to building an unparalleled model of scientific partnership with our clients.
  • At Immunologix, she will build on that experience to lead project management, business operations and scientific content development efforts for the Translational Sciences team.
  • Immunologix Laboratories is a unique scientific partner, offering GLP and GCP compliant laboratory capabilities focused on ligand binding based bioanalysis and expert scientific consultation from our Translational Sciences team.

Global Clinical Mass Spectrometry Market | $ 1.70 Billion Growth During 2020-2024 | Technavio

Tuesday, January 5, 2021 - 1:50am

The increasing use of mass spectrometry is expected to drive the growth of healthcare facilities and pharma and biotech companies, thereby boosting the growth of the market in focus.

Key Points: 
  • The increasing use of mass spectrometry is expected to drive the growth of healthcare facilities and pharma and biotech companies, thereby boosting the growth of the market in focus.
  • Increased R&D in the pharmaceutical industry and focus of laboratories on clinical research studies that use clinical mass spectrometry for analyzing the structures of proteins, nucleic acids, and small molecules will significantly drive clinical mass spectrometry market growth in this region over the forecast period.
  • Market growth in this region will be faster than the growth of the market in North America.
  • Related Reports on Health Care Include:
    Mass Spectrometry Market by End-user and Geography - Forecast and Analysis 2020-2024: The mass spectrometry market size has the potential to grow by USD 2.17 billion during 2020-2024.

Discovery Bioanalysis: Current Challenges and Emerging Opportunities for Biologics Quantification by LC-MS, Upcoming Webinar Hosted by Xtalks

Wednesday, October 28, 2020 - 12:30pm

The gold standard has been ligand binding assays (LBA), but liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is emerging as a promising alternative for biologics quantification.

Key Points: 
  • The gold standard has been ligand binding assays (LBA), but liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is emerging as a promising alternative for biologics quantification.
  • This webinar will highlight current challenges and emerging opportunities for the discovery environment.
  • For more information or to register for this event, visit Discovery Bioanalysis: Current Challenges and Emerging Opportunities for Biologics Quantification by LC-MS.
    Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Supporting the Development of Protein Drugs By LC-MS-Based Bioanalysis, Upcoming Webinar Hosted by Xtalks

Thursday, September 24, 2020 - 1:30pm

This webinar will give an overview of recent developments in the field of protein LC-MS, as applied to support the (pre)clinical development of macromolecular pharmaceuticals.

Key Points: 
  • This webinar will give an overview of recent developments in the field of protein LC-MS, as applied to support the (pre)clinical development of macromolecular pharmaceuticals.
  • The effect of proteinprotein interactions, biotransformation and the occurrence of protein isoforms on the analytical result will be addressed.
  • For more information or to register for this event, visit Supporting the Development of Protein Drugs By LC-MS-Based Bioanalysis.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Dr. Steven Yu Joins ChemPartner as Vice President of Regulated Bioanalysis

Thursday, September 17, 2020 - 4:05pm

SHANGHAI, Sept.17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Steven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters in Shanghai, China.

Key Points: 
  • SHANGHAI, Sept.17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Steven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters in Shanghai, China.
  • Prior to joining ChemPartner, Dr. Yu spent most of his career in the US with global pharmaceutical companies including Amgen, Boehringer Ingelheim, Shire, and Takeda.
  • To better serve our clients, including biologics clients, we needed an experienced industry leader to expand our service offering within regulated bioanalysis.
  • Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan

Dr. Steven Yu Joins ChemPartner as Vice President of Regulated Bioanalysis

Thursday, September 17, 2020 - 4:01pm

SHANGHAI, Sept.17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Steven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters in Shanghai, China.

Key Points: 
  • SHANGHAI, Sept.17, 2020 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Steven Yu, Ph.D. as Vice President of Regulated Bioanalysis at the company headquarters in Shanghai, China.
  • Prior to joining ChemPartner, Dr. Yu spent most of his career in the US with global pharmaceutical companies including Amgen, Boehringer Ingelheim, Shire, and Takeda.
  • To better serve our clients, including biologics clients, we needed an experienced industry leader to expand our service offering within regulated bioanalysis.
  • Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan